Discovering Granzyme K as a Potential 4th Complement Pathway
Time: 4:00 pm
day: Conference Day One
Details:
- Granzyme K as an activator of the complement cascade through the cleavage of C2 and C4 proteins
- Detailing the specific biomarker strategy employed in Empasiprubart trials for MMN, highlighting how these markers are used to assess disease activity, predict treatment response, and monitor therapeutic impact
- Exploring the implications of the biomarker strategy for future clinical practice, discussing how these insights could lead to more precise patient selection, personalized dosing, and improved long-term management of MMN
